EGFR and non-small cell lung carcinoma: In this challenging environment, options for the subsequent treatment of EGFR-mutant NSCLC will vary depending on the type and extent of disease progression [6] and may include: definitive local therapy (e.g., stereotactic ablative radiotherapy or surgery) for limited lesions; continuation of first-line treatment if it has some benefit (e.g., erlotinib, afatinib, gefitinib, or osimertinib unless the cancer is widespread, and continuing dacomitinib unless the cancer is in the brain/widespread); or switching to a different targeted therapy.